INTRODUCTION: SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptor, affecting multiple organs, including the cardiovascular system. Arterial hypertension is one of the most common and significant comorbidities, increasing the risk of severe disease progression and mortality.
AIM: The aim of this article is to analyze the interaction between COVID-19 and the cardiovascular system, with a focus on the role of arterial hypertension, the impact of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs), and the cardiovascular complications observed in COVID-19 patients.
MATERIAL AND METHODS: A review of current literature and clinical observations related to cardiovas-cular involvement in COVID-19 was conducted, with emphasis on comorbid hypertension, pharmacological management, and the nature of cardiac complications reported during the pandemic.
RESULTS AND DISCUSSION: Early concerns that ACEi and ARBs might worsen COVID-19 outcomes were not confirmed; instead, these medications are now considered safe and potentially protective. COVID-19 has been frequently associated with cardiovascular complications such as myocardial infarction, myocarditis, arrhyth-mias, and thromboembolism. Notably, some cardiac injuries occur in the absence of typical coronary artery obstruction, suggesting direct viral or immune-mediated damage. Furthermore, many patients delayed seek-ing care for acute cardiac events due to fear of infection, leading to worse clinical outcomes. Elderly patients with preexisting cardiovascular conditions remain at the highest risk.
CONCLUSION: COVID-19 and cardiovascular diseases have a mutually deleterious relationship. Arterial hy-pertension is a major and significant risk factor for severe COVID-19 outcomes. Maintaining good blood pres-sure control and continuing prescribed cardiovascular therapies during COVID-19 infection are essential for improving recovery and reducing the risk of fatal outcomes.
World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. Geneva: World Health Organization; 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154. doi:10.1038/s41579-020-00459-7.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-793. doi:10.1001/jama.2020.12839.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Cically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052.
Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature. 2020;583(7815):282-5. doi:10.1038/s41586-020-2169-0.
Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol. 2021;19(8):528-45. doi:10.1038/s41579-021-00535-6
CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343–6. doi:10.15585/mmwr.mm6912e2.
Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2):taaa021. doi:10.1093/jtm/taaa021.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. doi:10.1038/s41586-020-2012-7
Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202(5):756-9. doi:10.1164/rccm.202001-0179LE.
Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16(7):e9610. doi:10.15252/msb.20209610.
Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097-100. doi:10.1093/cvr/cvaa078.
Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. doi:10.1002/path.1570.
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-82. doi:10.7326/M20-0504.
National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda (MD): NIH. Available from: https://www.covid19treatmentguidelines.nih.gov/
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi:10.1016/S0140-6736(20)30566-3.
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi:10.1056/NEJMoa2002032.
Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. Published 2020 May 22. doi:10.1136/bmj.m1985.
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5. doi:10.1016/j.ijid.2020.03.017.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi:10.1016/S0140-6736(20)30628-0.
Centers for Disease Control and Prevention (CDC). People with Certain Medical Conditions. CDC COVID-19 Science Briefs. Updated 2023 Nov 2. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html
Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003-17. doi:10.1016/S2214-109X(20)30264-3.
Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198. Published 2020 Mar 26. doi:10.1136/bmj.m1198.
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. Published 2020 May 22. doi:10.1136/bmj.m1966
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5.
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-8. doi:10.1007/s00392-020-01626-9.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9. doi:10.1001/jama.2020.6775.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. doi:10.1001/jama.2020.2648.
Zhao M, Wang M, Zhang J, Gu J, Zhang P, Wang Y, et al. Comparison of clinical characteristics and outcomes of COVID-19 patients with and without hypertension in Wuhan, China: a retrospective cohort study. Hypertension. 2020 Nov;76(5):1220–9. doi:10.1161/HYPERTENSIONAHA.120.15631.
South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084-90. doi:10.1152/ajpheart.00217.2020.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653-9. doi:10.1056/NEJMsr2005760.
Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81(5):537-40. doi:10.1002/ddr.21656.
Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension. 2014;64(6):1368-75. doi:10.1161/HYPERTENSIONAHA.114.03743.
Roden M, Benzing T, Boor P. The COVID-19 pandemic: molecular and cellular mechanisms of the SARS-CoV-2 virus and implications for the kidney. Kidney Int. 2021 Jan;99(1):3–15. doi:10.1016/j.kint.2020.09.015 .
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;5(7):831-40. doi:10.1001/jamacardio.2020.1286.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061–9. doi:10.1001/jama.2020.1585.
Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543-58. doi:10.1038/s41569-020-0413-9.
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802–10. doi:10.1001/jamacardio.2020.0950.
Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, et al. ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes. Circulation. 2020;141(25):2113-6. doi:10.1161/CIRCULATIONAHA.120.047525.
Daniels MJ, Cohen MG, Bavry AA, Berman DS. Reperfusion of ST-Segment–Elevation Myocardial Infarction in the COVID-19 Era: Consensus from the North American COVID-19 STEMI Registry. Circulation. 2020 Jul 14;142(2):178–180. doi:10.1161/CIRCULATIONAHA.120.048227.
Garcia S, Albaghdadi MS, Meraj PM, Schmidt C, Garberich R, Jaffer FA, et al. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic. J Am Coll Cardiol. 2020 Jun 9;75(22):2871–2. doi:10.1016/j.jacc.2020.04.011.
De Filippo O, D’Ascenzo F, Angelini F, Bocchino PP, Conrotto F, Saglietto A, et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med. 2020 May 28;383(1):88–9. doi:10.1056/NEJMc2009166.
Baldi E, Sechi GM, Mare C, Canevari F, Brancaglione A, Primi R, et al. Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy. N Engl J Med. 2020;383(5):496-8. doi:10.1056/NEJMc2010418.
Marijon E, Karam N, Jost D, Perrot D, Frattini B, Derkenne C, et al. Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study. Lancet Public Health. 2020;5(8):e437-43. doi:10.1016/S2468-2667(20)30117-1.
Lai PH, Lancet EA, Weiden MD, Webber MP, Zeig-Owens R, Hall CB, et al. Characteristics Associated With Out-of-Hospital Cardiac Arrests and Resuscitations During the Novel Coronavirus Disease 2019 Pandemic in New York City. JAMA Cardiol. 2020;5(10):1154-63. doi:10.1001/jamacardio.2020.2488.
Email this article (Login required) 
